

Distinguished psychiatry professor David Castle appointed to Tryp's Scientific Advisory Board

- Professor David Castle, a leading scholar in psychiatry, has been appointed to the Company's Scientific Advisory Board for a three-year term
- Professor Castle is one of Australia's most distinguished psychiatrists with 20 years of experience at the University of Melbourne, including 15 years as Professor of Psychiatry from 2006 to 2021
- He is one of Australia's most published researchers in the field of mental health, having produced over 900 scientific articles and having a demonstrated track record of success in attracting grant funding for research programs
- Professor Castle has a specific interest in the application of psychedelic treatments to treat medical disorders and is currently one of the lead clinicians for a range of ongoing clinical studies utilising oral psilocybin, both in Australia and Canada
- He sees the potential for psychedelic therapies for a range of mental health issues, and notably the mechanism of action of these compounds facilitating a true integration of biological and psychological paradigms
- Professor Castle is an Honorary Professorial Fellow of the Department of Psychiatry, University of Melbourne; Honorary Professor, Department of Psychiatry, University of Cape Town; Clinical Professor, University Western Australia School of Psychiatry & Clinical Neurosciences & Adjunct Professor, Faculty Health, Arts & Design, Swinburne University
- As a member of the Scientific Advisory Board, Professor Castle will provide oversight and recommendations on the Company's ongoing clinical trial pipeline and expertise on grant funding

Melbourne, Australia – Tryptamine Therapeutics Limited ('Tryp' or the 'Company') (ASX: TYP), a clinical-stage biotechnology company focused on the development of an innovative and scalable intravenous-infused psilocin formulation which can be used in conjunction with psychotherapy to address significant unmet medical needs, is pleased to announce the appointment of Professor David Castle to its Scientific Advisory Board ('SAB').

Professor Castle is a leading psychiatric scholar who was recently appointed by the Tasmanian Government as Professor of Psychiatry at the University of Tasmania's Centre for Mental Health Service Innovation, which was launched in partnership with the Tasmanian Department of Health.

In 2021, he was recruited to serve as the Inaugural Scientific Director at the Centre for Complex Interventions (CCI) and the Centre for Addictions and Mental Health (CAMH) at the University of Toronto. Prior to that, he had a 20-year career as the Professor of Psychiatry at the University of Melbourne.

Throughout his career, Professor Castle has focused his clinical and research work on mental health conditions including schizophrenia and related disorders, bipolar disorder, and the obsessive-compulsive disorder (OCD) spectrum. In particular, he has a major current interest in psychedelic treatments to achieve improved health outcomes in the field of psychiatry. He is also pursuing his work on OCD spectrum disorders, notably body dysmorphic



disorder, in which he is a recognised international expert (ranked 1st globally on Expertscape).

Professor Castle is currently one of the lead clinicians for an ongoing psychedelic clinical study utilising oral psilocybin in OCD. Comprising 160 patients, the three-arm, placebo-controlled study is the largest single study for OCD globally. He has also provided input into a second clinical study (scheduled to commence soon) that gained grant support from the Australian Government for oral psilocybin's use in Anorexia Nervosa.

As one of Australia's leading researchers in mental health, he has published more than 900 articles and book chapters and is a regular reviewer for over 30 national and international scientific journals. Over the course of his career, he also has a demonstrated track record of attracting continuous and significant grant funding for research projects.

Professor Castle has agreed to terms to join the SAB for a period of three years. In his capacity as an SAB member, Professor Castle will provide expert consulting services with respect to best-practice for regulatory engagement and grant funding initiatives, in connection with Tryp's ongoing clinical trial program. His appointment follows the recent reappointment of Robin Carhart-Harris, PhD, a psychopharmacologist and globally recognised leader in psychedelics research, who renewed his role as Chair of the Company's Scientific Advisory Board for a three-year term (refer ASX Announcement 26 June 2024).

Management commentary:

Chief Executive Officer, Mr. Jason Carroll said: *"It's my pleasure to welcome Professor Castle to Tryp's Scientific Advisory Board, marking another high calibre appointment to guide the strategic direction of the Company in pursuit of our stated clinical development strategy. In discussions with the Tryp management team and incumbent members of the SAB, Professor Castle has showed a high level of interest in the potential for use of IV-infused psilocin in terms of supporting both patients and clinicians as well as the potential for it to be viewed positively by the TGA for potential registration and reimbursement."*

"The Tryp team have enjoyed discussions with Professor Castle to date and appreciate the strength and breadth of his knowledge and expertise. We strongly believe that his addition to our SAB will be truly beneficial, not just due to his professional input to the Company's clinical program, but also in the support of patients and clinicians as we develop a path for the registration, approval and clinical use of IV-infused psilocin for those that are in medical need."

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803



(IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience. TRP-8803 is currently being evaluated in a Phase 1 Healthy Volunteer Study in Adelaide, Australia.

For more information, please visit www.trypttherapeutics.com.

Investor & Media Contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@trypttherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.